98%
921
2 minutes
20
Objective: We examined characteristics of depressive symptoms in patients who received left ventricular assist devices (LVAD) to assess their effects on negative outcomes post-implantation.
Methods: We retrospectively identified 203 adults with pre-operative PHQ-9 scores who underwent LVAD placement as bridge to transplant (BTT) or destination therapy (DT). We analyzed effects of PHQ-9 total, somatic, and cognitive/affective scores and proportion of patients with clinical depression on all-cause mortality, rehospitalization, major bleeding, and neurologic events post-implantation, controlling for demographics and other medical comorbidities.
Results: Mean total PHQ-9 scores did not differ between 81 BTT and 122 DT patients (BTT 6.4 vs. DT 7.5, p = 0.12). A higher proportion of DT patients had clinical depression (BTT 22% vs. DT 39%, p = 0.015). Somatic symptoms accounted for three-quarters of total scores in both groups. PHQ-9 domains were not associated with negative outcomes post-implantation.
Conclusion: Depression severity did not differ based on implant strategy, but more DT patients had clinical depression. Somatic symptoms were the biggest contributor to depressive symptoms. Pre-implantation PHQ-9 scores were not associated with outcomes, possibly because depression was mild in both groups. Additional work is needed in LVAD patients to better characterize depressive symptoms and their unique effects on clinical course and well-being.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.genhosppsych.2019.12.005 | DOI Listing |
J Neural Transm (Vienna)
September 2025
Parkinson's Foundation Centre of Excellence, King's College Hospital, Denmark Hill, London, SE5 9RS, UK.
Parkinson's disease patients are at increased risk of road traffic and car accidents and those with excessive daytime sleepiness are specially susceptible. Abnormal scores on the Epworth Sleepiness Scale predicts risk for driving-related somnolence which may cause road traffic accidents in driving patients as many such patients declare dozing of while in a car. Our study estimates that over 40% of patients with daytime somnolence have risks of dozing off in a car.
View Article and Find Full Text PDFJ Neural Transm (Vienna)
September 2025
Sárospatak College, Sztárai Institute, University of Tokaj, Eötvöst str. 7, Sárospatak, 3944, Hungary.
Generalized Anxiety Disorder (GAD) is characterized by excessive worry and physical symptoms of prolonged anxiety. Patients with subclinical GAD-states (sub-GAD) do not fulfill the diagnostic criteria of GAD, but they often show a disease burden similar to GAD, and the subclinical state may turn into a full syndrome. Neuroinflammation may contribute to changes in brain structures in sub-GAD, but direct evidence remains lacking.
View Article and Find Full Text PDFMol Psychiatry
September 2025
National Center for PTSD, Behavioral Science Division, VA Boston Healthcare System, Boston, MA, 02130, USA.
Glial fibrillary acidic protein (GFAP) is an astrocytic marker that can be assessed in blood using single molecule array technology. Recent studies suggest that individuals with posttraumatic stress disorder (PTSD) have suppressed circulating levels of this CNS biomarker. This study examined the hypothesis that PTSD and plasma GFAP levels share common genetic and epigenetic pathways.
View Article and Find Full Text PDFOccup Environ Med
September 2025
National Institute of Occupational Health, Oslo, Norway.
This systematic review examined the impact of unemployment and re-employment on mental health problems (depression, anxiety and psychological distress) among working-age adults. We searched MEDLINE, Embase, APA PsycINFO and Web of Science (January 2012-March 2024) and included studies from a prior meta-analysis (1990-2012). Risk of bias was assessed using the Newcastle-Ottawa Scale.
View Article and Find Full Text PDFEur Urol Focus
September 2025
Department of Urology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.
Background And Objective: While whole-gland therapies for localized prostate cancer (PCa) offer excellent oncological outcomes, these can impact patients' quality of life (QoL) through serious side effects. Focal therapy using high-intensity focused ultrasound (HIFU) has emerged as a less invasive alternative to preserve QoL. However, data on the psychological impact of HIFU remain rare.
View Article and Find Full Text PDF